PI 3-Kinase Cancer Immunotherapy
Pancreatic cancer patients will be treated with a PI3K inhibitor to induce the cancer cells to reveal their antigens to the immune system Background: Standard chemotherapies have little impact on pancreatic cancer (PDAC) patient survival, and new T-cell therapies have yet to be successful in treating solid tumors. Phosphoinositide 3-kinase (PI3K),...
Published: 2/29/2024
|
Inventor(s): Richard Lin
Keywords(s): cancer, immunotherapy, phosphoinositide 3-kinase (PI3K), PI3K inhibitors, Technologies
Category(s): Campus > Stony Brook University, Technology Classifications > Gene Therapy and Viral Vectors, Technology Classifications > Therapeutics
|